🔥Telegram İfşa

💓 Focused on reducing the reducing the physical, emotional, and economic burdens of obesity. 🔬 Metsera Inc. is a biopharmaceutical company accelerating the next generation of obesity and metabolic disease medicines. 🥳 So proud to be your exchange partner, $MTSR! Welcome to

An exciting day for Metsera as we celebrate our official listing on Nasdaq Exchange as $MTSR! This marks an important step for the company and we extend thanks to our team and partners for their support in achieving this milestone.

Obesity impacts over a billion people worldwide, leading to significant physical, emotional, and economic burdens on individuals and society. At Metsera, our purpose is to reduce these burdens by developing trusted, convenient, and accessible medicines. This #WorldObesityDay, we

This morning, we announced our fourth quarter and full year 2024 financial results and continued portfolio progress on our lead program, MET-097i as well as our earlier-stage product candidates. For more details, read the full press release here: investors.metsera.com/news-releases/…

Metsera CEO Whit Bernard recently joined Brad Loncar on @BiotechTVHQ to talk about what sets Metsera apart. Whit shares how we’re advancing a broad portfolio of therapies with potential best-in-class profiles to meet the future needs of a rapidly evolving weight loss treatment

This morning, we rang the Nasdaq #OpeningBell in celebration of $MTSR’s listing. It was a proud & symbolic moment for us, highlighting the dedication of our team & our continued focus on addressing the burden of #obesity with trusted, accessible medicines. Thank you to our

Today, we reported our first quarter 2025 financial results and continued portfolio progress. We remain on track to deliver on all of our committed clinical milestones for 2025. For more details, read the full press release here: investors.metsera.com/news-releases/…

We are excited to attend the 85th #ADASciSessions in Chicago on June 20 - 23. We will highlight the breadth and momentum of our portfolio of ultra-long acting, scalable, and combinable therapies, including updated clinical and preclinical findings from lead program MET-097i.

We are pleased to share positive Phase 1 data of first-in-class once-monthly amylin candidate MET-233i, which was engineered for class-leading durability, potency, and combinability with Metsera's fully-biased monthly GLP-1 RA candidate MET-097i. MET-233i demonstrated up to 8.4%

Metsera CEO Whit Bernard will present at the Goldman Sachs 46th Annual Global Healthcare Conference on June 11 at 10:00 - 10:35 A.M. ET. To access the live webcast, visit investors.metsera.com.

Metsera CEO Whit Bernard sat down with @BradLoncar at @BiotechTVHQ to discuss what’s next in obesity care, & how we’re helping shape that future. Whit shares updates on our pipeline, including highlights from ADA & why we believe oral peptides with injectable-like performance can

Today, we reported our second quarter 2025 financial results and continued portfolio progress. Notably, we are on track towards all upcoming clinical milestones, including a Phase 2b VESPER-1 and interim VESPER-3 readout of MET-097i in September, followed by a planned global

Metsera CEO Whit Bernard will present at the following investor conferences next week: 🔸 Cantor Global Healthcare Conference 2025 on September 3, 2025, at 3:20-3:50 pm ET. 🔸 Wells Fargo 2025 Healthcare Conference on September 4, 2025, at 4:30-5:05 pm ET. To access the live

We are excited to attend #EASD2025 in Vienna on September 15-19. We will present clinical and preclinical data from our portfolio of next-generation ultra-long acting, scalable, and combinable therapies, including a late-breaker on the initial efficacy observed for our amylin

Today, we announced that Metsera has entered into an agreement to be acquired by Pfizer. With our portfolio of differentiated oral and injectable nutrient-stimulated hormone therapeutic candidates, we believe Pfizer's global capabilities will help accelerate our purpose to

Today, we announced positive topline data from VESPER-1 and positive data from a planned interim analysis of VESPER-3 – two phase 2b trials of MET-097i. The favorable data in both trials support the advancement of MET-097i into Phase 3 clinical trials & accelerate its development

Metsera is now part of Pfizer! Thank you for being a follower, and please consider following us @Pfizer and @Pfizer_news for future updates. pfizer.com/news/press-rel…